Edible Vaccines and the Chemical Engineering of Plant-Based Biopharmaceuticals: Emerging Molecular and Process Innovations

Godfrey EO [1*], Obinna CJ [2], Saleem AA [3], Imuetinyan U [4], Francis CO [5], Ademola RO [6], Temitope PO[7], Barnabas O [8], Muhammad IA [9], Guillaume NN [10]

[1, 2] Department of Biochemistry, University of Benin, 302001, Nigeria
[3] Chemical Engineering, Ladoke Akintola University of Technology, 210214, Nigeria
[4] Department of Microbiology, Ambrose Alli University, Ekpoma, 310101, Nigeria
[5] Biomedical Engineering, Afe Babalola University, Ekiti, 360102, Nigeria
[6] Biomedical Engineering, Ulster University, BT15 1AP, United Kingdom
[7] Department of Zoology, University of Ilorin, 240003, Nigeria
[8] Department of Pharmacology, Delta State University, Abraka, 334103, Nigeria
[9] Department of Biological Sciences, University of Bergen, 5020, Norway
[10] Food Biotechnology, Ural Federal University, 620062, Russia

* Corresponding Author: **Godfrey EO**

Article Info

ISSN (online): 3049-0421
Volume: 02
Issue: 05
September – October 2025
Received: 01-07-2025
Accepted: 03-08-2025
Published: 02-09-2025
Page No: 01-14

Abstract
Leveraging molecular pharmaceutics, chemical engineering processes, and molecular biology, edible vaccines are currently revolutionizing vaccine delivery paradigms. Current developments optimize production, post-translational modifications, and immunological efficacy by focusing on antigen manufacturing at the nuclear and chloroplast compartments. Reliable mucosal uptake is made possible by chemical stabilization techniques that address gastrointestinal breakdown, most notably nanostructured cellulose encapsulation and biopolymer matrices. Adaptability against region-specific disease burdens is improved by novel crop systems that can deploy switchable genetic modules or stack multi-antigen complexes. Concurrently, the incorporation of micronutrient-rich matrices adds a distinct immuno-nutritional component to the effectiveness of vaccines. With the application of digital traceability infrastructures and biosafety regulations that reduce the hazards of environmental dissemination, process engineering is evolving towards scalable, GMP-aligned field manufacturing. These synergistic molecular and process breakthroughs collectively frame edible vaccines as an emergent biopharmaceutical modality with profound implications for decentralized, low-cost, and widely accessible immunization strategies. This review provides insight into translational pathways, biosafety strategies, and future objectives for clinical integration by clarifying new molecular and technological advancements in plant-based edible vaccines.

DOI: https://doi.org/10.54660/IJPGRR.2025.2.5.01-14

Keywords: Plant-Derived Antigens, Edible Vaccine Crops, Polyvalent Vaccine Crops, Antigen Deployment

1. Introduction

More than 3 decades ago, when the first reports of plant manufacture of mammalian proteins surfaced, the term plant molecular farming has been used to describe the idea of using plants as biological factories. The term “biopharming”, or molecular farming was first used by Fischer *et al*, to refer to the production of recombinant proteins in plants [1, 2]. Early efforts focused on recombinant macromolecules, including blood proteins, vaccines, and antibodies, but the scope has expanded to include raw materials for cosmetics and therapeutic agents.

In order to improve immunity against some specific sicknesses and diseases, vaccines are used which are biological substances that are designed to stimulate the production of antibodies in both humans and animals [3, 4]. However, millions of individuals in underdeveloped and low-income countries of the world have not been completely protected by vaccination due to issues like storage and high cost. It has been accounted that an estimated 20% of newborn remain unvaccinated, which has led to over 2 million preventable deaths annually [5]. These challenges with conventional vaccines include high production cost, cold-chain dependence, and—in the case of some DNA vaccines—variable efficacy and occasional adverse immune reactions [6, 7]. These limitations have driven the search for safe, easily administered, and stable alternatives, leading to the innovative concept of using plants as efficient vaccine production systems—giving rise to edible vaccines [8]. Oral vaccines are more affordable and accessible, particularly in developing countries. This has inspired the plant-based edible vaccines, where edible plant parts serve as biofactories for antigen production [9]. Antigen-expressing plants require basic agricultural knowledge for cultivation and bypass the costly purification and downstream processing steps of conventional vaccines, making them a promising alternative [10, 11, 12].

Edible vaccines are typically generated in transgenic plants and less commonly, in animals-and contain antigenic components capable of stimulating an immune response. In summary, edible vaccinations are biopharmaceuticals made from plants or animals.

2. Plant Organelles Genomic Engineering of Antigen Expression

2.1. Chloroplast Engineering of High-Density Expression

Protein products with clinical or veterinary uses are produced via recombinant plant systems. These plant systems are broadly categorized as those that use plant

1. Viral technology
2. Chloroplast transplastomic technology
3. Nuclear transgenic technology.

The stably integrated nuclear transgenes produce a relatively low level of recombinant proteins (less than 1% of total soluble protein, TSP), probably due to gene silencing or position effects [13]. In a plant viral vector system, recombinant proteins are transient and at a higher level than those of stably integrated nuclear transgenes.

Chloroplast genetic engineering has become a more advanced and potent method for achieving exceptionally high levels of recombinant protein expression in plants. Double homologous recombination is necessary for chloroplast genome transformation, where transgenic cassettes are integrated into specific intergenic spacer regions, guided by flanking sequences from chloroplast DNA, without interfering with any functional genes, and as such, there is a much higher level of protein expression in chloroplasts, enabled by more than 10,000 copies of transgenes in each transformed plant cell [14-16]. The intergenic spacer region between the trnI–trnA genes in the rrn operon has emerged as one of the most commonly used integration sites among the many integration sites examined, and further benefits of this locus include enhanced copy number via replication origin and correction mechanisms within the inverted repeats that improve homoplasmy [15-22].

Regulatory sequence selection also influences the efficiency of high-density expression. To further increase translation efficiency, the heterologous bacteriophage T7 gene 10 leader sequence has been used, and the chloroplast psbA promoter with its 5′ and 3′ UTRs continues to be one of the most useful tools [22, 23, 24].

A significant benefit of chloroplast engineering for molecular farming is that it removes expression variation across independent transgenic lines; no reports of gene silencing have been documented in chloroplast transgenic (transplastomic) lines [25]. Moreover, because transgenes are usually inherited maternally, it reduces the risk of foreign genes spreading through pollen. Although traditionally focused on protein hyperexpression, chloroplast engineering's high transcription capacity also makes it a valuable platform for producing double-stranded RNA (dsRNA).

Chloroplast engineering for high-density expression combines precise genome targeting, strong regulatory control, coding optimization, multigene stacking, and efficient marker management to achieve some of the highest recombinant protein yields in plants, while extending chloroplast engineering beyond protein hyperexpression to dsRNA production broadens its applications in agriculture and biomedicine [26]. Field studies showed that plastid-derived dsRNA could protect against the potato beetle, highlighting the translational potential of this approach [26].

The design of coding sequences is another important consideration in optimizing chloroplast expression. For example, genes with more than 10 introns can now be expressed directly in plastids without the need for cDNA libraries thanks to the removal of introns from eukaryotic genes using overlapping-primer PCR [27]. Furthermore, it is noteworthy that some of the highest expression levels have been achieved utilizing unaltered native coding sequences, including

those from humans [28], even though codon optimization can occasionally enhance expression [29]. Chloroplast engineering is now much more efficient thanks to developments in vector construction, regulatory design, and coding optimization.

Moreover, polycistronic constructs are widely used for multigene engineering, and even without intercistronic expression elements (IEEs), high-level expression of several heterologous multigene constructs has been achieved, suggesting that simplified polycistronic designs are adequate for effective translation [20, 21, 30]. Selectable marker systems are also necessary for transplastomic line recovery, and the most reliable marker across species is the aadA gene that confers spectinomycin resistance [31, 32]. The exact removal of selection cassettes from the chloroplast genome has been made possible by the application of marker removal techniques, including direct repeats, Cre-lox recombination, and most recently, Bxb1 recombinase-mediated excision, to refine genetic constructs [33, 34].



Fig 2.1: The Art of Chloroplast Genome Engineering [161]

2.2. Nuclear-Encoded Expression with Targeted Post-Translational Modification

The best characterized PTM in eukaryotes is reversible phosphorylation, which is essential for almost every cellular function in the eukaryotic cells and is mediated by the enzymatic activities of kinases and phosphatases. Approximately 1,000 genes in plants encode potential kinases that phosphorylate residues of Ser, Thr, and Tyr [35]. Nevertheless, chloroplast phosphoproteomics has shown that there is no detectable Tyr phosphorylation and that 72% are Ser-phosphorylated and 27% are Thr-phosphorylated [36]. PSII repair under high light conditions depends on the phosphorylation of PSII core proteins, particularly D1, whereas reversible light-dependent phosphorylation of LHC proteins controls the excitation balance between PSII and PSI [37, 38, 39, 40, 41]. These processes are mediated by the kinases STN8 and STN7 and the LHC phosphatase has been defined [42, 43]. It is essential to know that phosphorylation plays a crucial function in chloroplast metabolism: other chloroplast phosphoproteins include transcription, calcium signaling and regulators of cyclic electron transport [44, 45].

The three types of acetylation -O-, Nα-, and Nε-acetylation (Lys acetylation)—all require acetyl CoA as a substrate. Nα-acetylation is one of the most common protein modifications in eukaryotes and is irreversible [46, 47]. Protein stability and pI are impacted as it neutralizes the positive charge at the N-terminus. NAT complexes often linked to ribosomes catalyze it in plants [48]. It may control interactions, targeting and protein half-life [48, 49, 51, 52]. Developmental abnormalities are caused by mutations in NATB [53, 54]. Nα-acetylation takes place in chloroplasts in three different ways: cotranslational acetylation of preprotein transit peptides, Nα-acetylation essential for import and Nα-acetylation preventing cytosolic accumulation in TOC159 mutants [55, 56, 57].

Methylation occurs when methyl groups are transferred to Lys or Arg residues by methyltransferases [58, 59]. Arg demethylases are yet unknown but Lys demethylases have been found [60]. Protein stability, localization, or interactions may be impacted by this modification, which increases the hydrophobicity and basicity of residue [61]. Some species' Lys-14 is trimethylated in chloroplasts by Rubisco large subunit methyltransferase (RLSMT), albeit its functional implications are still unknown. Lys methylation is also present in FRU-1,6-bisphosphate aldolase isoforms, but it has no effect on activity [62, 63].

Nitration; two NO-dependent PTMs important in signaling are Tyr nitration and S-nitrosylation. By adding a nitro group to Tyr, Trp, Cys, or Met, nitration modifies the hydrophilicity and charge of the residue [64, 65]. Tyr nitration is mediated by peroxynitrite (ONOO–), which is formed when superoxide and NO combine [66]. Nitrated Tyr residues are frequently found in loop regions close to basic residues and negative charges [67]. These modifications integrate with other PTMs to regulate protein function dynamically.

Glycosylation, once considered absent in chloroplast proteins, has now been demonstrated in certain nuclear-encoded proteins that are imported through the ER–Golgi pathway. N-glycosylation, observed in carbonic anhydrase and α-amylases, plays a crucial role in protein folding and stability [68, 69, 70, 71, 72]. Additionally, O-glycosylation has been reported in P43 DNA-binding proteins [73]. These findings reveal that nuclear-encoded chloroplast proteins can undergo regulation by multiple cellular compartments and pathways, underscoring the coordinated role of PTMs in chloroplast function.

Chloroplast proteins like ferredoxin, PSI, and PSII have been shown to undergo sumoylation, however this process has received less attention [74,75]. Sumoylation is believed to

take place in the cytoplasm prior to protein import [76], where it plays a role in modulating protein localization and interactions. Collectively, the wide range of PTMs—including phosphorylation, acetylation, methylation, nitration, glycosylation, and sumoylation—demonstrates the intricate regulation of nuclear-encoded proteins within chloroplasts, integrating processes such as photosynthesis, metabolism, development, and responses to stress.



Fig 2.2: PTMs overview in the chloroplast [162]

3. Chemical Stability and Bioencapsulation of Plant-Derived Antigens

Chemical stability and bioencapsulation are strategies designed to protect plant-derived antigens from adverse environmental conditions, while enabling controlled release and targeted distribution. The chemical stability approach prevents plant-derived antigens from degrading due to oxidation, pH changes, or enzymatic activity through the application of chemical substances such as stabilizers that inhibit protein aggregation, cryoprotectants, or antioxidants. For instance, trehalose can be added to a plant-based vaccine formulation to prevent damage during freeze-drying and storage [77-78].

The use of suitable carriers, referred to as drug delivery vehicles (DDVs), facilitates the interaction of drugs and vaccines with specific targets. The choice of delivery route determines the most appropriate DDV. While many drugs are administered directly into the bloodstream, others are administered orally, with oral administration often preferred due to its convenience, non-invasiveness, and ease of dosage control [79]. Since oral delivery places additional demands on the drug, such as oral bioavailability, stomach acid resistance, and resistance to digestive enzymes, the DDV's job is to overcome these barriers while protecting the drug and, if necessary, preventing premature release that could result in off-target effects.

Numerous prospects for the manipulation of innovative DDVs are presented by plants' ability to support bioencapsulation at the cellular and subcellular levels, as well as the synthesis of proteinaceous nanoparticles. The high levels of lignin and cellulose in plant cell walls provide exceptional resistance to enzymatic digestion and physical stress. Therefore, encapsulating drugs and vaccines in plant cells not only protects them during transit through the upper digestive tract but also enables drug delivery to the intestinal lining. Although plants are widely consumed, commensal gut bacteria are necessary for accessing the nutrients found in plant cells. The binding of encapsulated protein to cell-specific ligands facilitates the absorption of drugs and vaccines into intestinal epithelial cells, delivery to mucosal immune cells, or passage through the endothelium into circulation, thereby supporting systemic immune response and enabling oral drugs to cross the blood-brain barrier [80].

Numerous subcellular compartments found within plant cell walls can also act as an extra line of defense. For instance, storage organelles enable the steady intracellular accumulation of proteins, lipids, and carbohydrates as well as other energy stores. Plant-derived polymers from storage organelles are also promising *in vitro* encapsulation materials. Zein, the major storage protein in maize seeds, has

been widely explored due to its distinctive physicochemical and biological properties. It forms edible films that are durable, hydrophobic, and resistant to microbial degradation, making it useful in food and pharmaceutical coatings [81]. Zein nanoparticles have been applied to encapsulate poorly soluble compounds such as curcumin [82], aceclofenac [83], quercetin [84], and α-tocopherol [82, 83, 84, 85]. Likewise, starch granules, which store energy-rich carbohydrates in plants, have been developed as DDVs alongside their polymers [86-87]. With excellent biocompatibility, starch polymers are utilized in various biomedical and pharmacological applications and starch microparticles have also demonstrated potential adjuvant activity [85, 88].

4. Immuno-Nutritional Synergies in Plant-Based Biopharmaceuticals

Chemical agents that can influence the immune system are referred to as immunomodulators, the chemical substances can decrease the aberrant immunological response that occurs in immune disorders or increase the immune defense to strengthen the body's responses against infectious or exogenous damage. Furthermore, by assisting the immune system in targeting nonimmune targets, immunoadjuvants can enhance the immune response. The microbiomes and inflammatory pathways can both be altered to help regulate immune function. The pleiotropic and multifaceted effects of several plant-based nutraceuticals have led to their investigation as potential immunomodulating drugs. A desirable nutraceutical strategy is their adjuvant contribution, which is typically more tolerated than pharmaceutical therapies (Di Sotto *et al*., 2020).

The immune system functions through both innate and adaptive mechanisms. Agents that modulate immunity may act either to suppress or stimulate immune activity. Immunosuppressants work by preventing activation or reducing the function of immune components, whereas immunostimulants enhance the body's natural defenses to maintain or restore homeostasis [90]. During the COVID-19 pandemic, vaccine-induced trained immunity was suggested as a method to strengthen antiviral protection [91]. Increasing research underscores the importance of the gut microbiome in immune regulation; disturbances in its balance are linked to disease, while enhancing it with prebiotic or probiotic supplementation supports immune resilience [92, 93]. This interplay between the microbiome and immunity exemplifies a key immuno-nutritional synergy.

Since ancient times, a number of medicinal plants and phytochemicals have been recognized for their capacity to modulate immune system function. In addition to promoting innate and adaptive humoral and cellular immunity, they also modulate the gut microbiota or disrupt proinflammatory pathways [94–96]. Examples are Curcuma longa, which contains curcuminoids that have IL-10 mediated anti-inflammatory activity, Panax ginseng, which contains triterpene saponins that stimulate cytokine activation and gut microbiome modulation and Echinacea purpurea, which contains alkylamides and polysaccharides that activate cellular immunity [94, 97, 98]. It has also been reported that Astragalus membranaceus, Withania somnifera, and other plants have immunostimulant properties [99, 100].

Polysaccharides are carbohydrate macromolecules that have immunostimulatory properties that depend on their chemical structure, molecular weight, and branching [101, 102]. For instance, Astragalus polysaccharides increase NK cell cytotoxicity and promote nitric oxide synthesis in macrophages [103, 104, 105]. Dietary fibers such as inulin and β-glucan are metabolized by the gut microbiota to produce short-chain fatty acids (SCFAs) that interact with GPR receptors on immune cells, modulating NF-κB and MAPK signaling [106, 107]. Long-chain fatty acids also exhibit immunomodulatory properties; oleic acid reduces NK activity and causes proapoptotic effects in lymphocytes [108–114], and conjugated PUFAs, such as punicic acid, stimulate CD4+ and CD8+ immunity through PPARγ/δ mechanisms [115, 116].

Clinical research demonstrates the potential of nutraceuticals produced from plants in biopharmaceutical applications. In cancer patients, astragalus therapy boosted NK cell activity [117]; products made from echinacea marginally decreased the risk and duration of colds [118, 119]. Supplementing children with long-term respiratory issues with β-glucan enhanced their immunity [120–122]. Cancer recurrence was reduced by Mannan-mucin 1 without causing any harm [123]. These results highlight how immuno-nutritional synergy are used by plant-derived nutraceuticals to modify both innate and adaptive immunity. Even though there is a lot of preclinical evidence, more excellent clinical research is required to completely determine their function in plant-based biopharmaceuticals.



Fig 4: Primary classes of plant-sourced nutraceuticals with immunomodulatory potential [163]

5. Multi-Antigenic and Modular Expression Systems

The administration of single antigens has today become the new paradigm for edible vaccines, which have experienced a remarkable transformation. However, integrated systems that can express several immunogens and dynamically regulate their deployment have been incredibly adopted in this field. An evolution of this kind demonstrates empirically the need for more flexible, broader-spectrum vaccination techniques in public health, particularly in areas where seasonal outbreaks are influenced by environmental factors and co-infections by numerous pathogens are still common. Engineered crops with multi-antigenic payloads and switchable modular structures offer a frontier in vaccine innovation within the plant-based biopharmaceutical landscape, allowing edible vaccines to precisely and scalable address complicated epidemiological scenarios.

5.1. Polyvalent Vaccine Crops: Genetic Stacking for Multi-Pathogen Protection

Today's polyvalent vaccine crops are developed to express immune responses against the same pathogen within a single plant matrix, neutralizing various pathogens. This is usually referred to as genetic stacking technique, a technique whereby several transgenes are integrated, encoding different antigenic proteins into a single host genome or organelle system. This is the general practice for this genetic stacking method. Furthermore, due to its high copy number and ability to integrate large operons for several antigenic genes without gene suppression, chloroplast transformation has proven especially invaluable in this aspect [124, 125]. For example, polycistronic chloroplast constructions that express the epitopes of bacteria, viruses, and protozoa have shown sustained, high-level expression of multivalent antigens while preserving the host plant's ability to photosynthesize [126].

Moreover, polyvalent crops have demonstrated essential epidemiological significance. Children are particularly vulnerable to respiratory infections, parasite infestations, and diarrheal illnesses in many endemic areas. The logistical challenges associated with multiple immunization campaigns may be lessened by developing and implementing crops that may co-express antigens against like the virus, rotavirus, the bacteria, Vibrio cholerae, and enterotoxigenic Escherichia coli in a single edible matrix [127]. Furthermore, the display of mosaic epitopes has been made possible by recent notable experimental progress in virus-like particles (VLPs) formed in plants, resulting in chimeric structures that provide cross-protection against different viral strains [128]. To ensure that correct folding and epitope exposure is achieved in a multivalent environment, practices like linker peptide engineering and codon harmonization are being widely adopted more and more to enhance this modularity in antigenic presentation [129].

In addition to its immunological effectiveness, polyvalent vaccine crops have, at industry level, shown to offer production efficiency. Typically, different antigens expressed by a single plant eliminate the need for different manufacturing lines, also simplifying downstream purification, and providing affordable production options in environments or ecosystems with limited resources. To balance immunogenicity across several targets, rational construct design and adjuvant integration are necessary due to antigenic competition, which might cause the immune response to be expressed in a biased manner toward a single dominant antigen [130].

5.2. Switchable Genetic Constructs: Seasonal or Region-Specific Antigen Deployment Through Modular Cassettes

Switchable genetic constructs, even though still witnessing modifications via research, is a method that concentrates on the regulated and context-specific deployment of antigens. Polyvalent crops on the other hand, handle exposure to multiple pathogens. To enable antigen expression only when necessary, these systems rely on two factors: inducible promoters and modular cassettes. These two can then be triggered by external stimuli such heat, light, chemical inducers, or developmental signals [131]. On a practical note, these structures enable crops to operate as vaccine reservoirs particular to a given location, generating antigens during seasonal epidemics, such as cholera during monsoon rains or influenza throughout cold seasons [132].

With research in this area still expanding, the fine-tuning of expression cassettes has been rendered much easier, owing to recent research advancements in synthetic promoter libraries, which allow for precision in the spatiotemporal control of antigen synthesis. For instance, it is now, even though novel, possible to effectively toggle protein expression in transgenic tobacco using ethanol-inducible promoters in a way that is scalable to agricultural systems [133]. In a similar vein, promoters powered by circadian rhythms are being studied to reduce the metabolic load on the plant host during non-essential phases by coordinating antigen synthesis with predictable environmental cycles [134]. The application of modular viral replicon systems, in which different antigen cassettes may be incorporated into a single viral backbone and spread across plant tissues, is a particularly promising approach. These systems essentially serve as "plug-and-play" vaccine platforms, enabling the quick substitution of antigenic components in response to new pathogen variations [135].

In situations involving pandemic preparedness, where prompt vaccine production is critical, this flexibility is vital. However, several biosafety concerns are raised simultaneously, when switchable structures are the adopted mechanism in edible vaccines. For example issues such as horizontal gene transfer, unexpected activation under environmental stress, and leaky promoter activity are still likely to occur, thereby calling for strict molecular protections and biocontainment techniques [136]. In order to improve safety while preserving the functional flexibility of modular vaccine constructions, future research approaches will involve incorporating digital traceability systems and genetic "kill switches."

6. Bioprocess Engineering for Controlled Agricultural-Scale Manufacturing

Only via the successful scaling of molecular discoveries in plant biotechnology can the potential of edible vaccines be realized on a worldwide basis, with particular attention to areas that are vulnerable to epidemiological outbreaks. A safe, economical, and reproducible production pipeline

would be necessary for this. Agricultural-scale production of plant-based vaccines is inherently diverse, which is nearly the opposite of conventional vaccine manufacture, where highly uniform growth settings are provided by microbial or mammalian cell bioreactors. In order to connect greenhouse systems or open-field cultivation with the Good Manufacturing Practice (GMP) requirements necessary for pharmaceuticals, bioprocess engineering techniques become crucial. This entails combining strict quality control, containment agriculture, and standardized supply chain models that guarantee biosafety and scalability. This section hence, broadly discusses available mechanisms, their operational module and areas of scientific interests.

Scalable Containment Agriculture Integrating GMP Compliance in Field-Based Production

Reconciling pharmaceutical uniformity with agricultural heterogeneity has over the years proven to be a major difficulty in the bioprocessing of edible vaccines. There are several reasons for this, however. Whether using hydroponic systems, vertical farming, or greenhouse facilities, controlled confinement agriculture provides a technique to reduce environmental changes while following GMP guidelines [137]. These technologies at very effective levels, reduce batch-to-batch variability which are often persistent challenges in antigen content by enabling predictable yields, controlled nutrient supply, and pest management without the use of broad-spectrum insecticides. Despite its economic utility and appeal, field-based production poses biosafety issues such as accidental environmental spread, cross-pollination, and accidental presence in the food chain [138].

Pharmaceutical-grade containment is being achieved by combining GMP monitoring procedures with procedures ranging from male sterility systems and plastid transformation (maternal inheritance) to greenhouse isolation units [139]. Also, adopting agricultural tools that are precise, including AI-driven crop monitoring, remote sensing, and soil moisture analytics, improves control even further and helps producers satisfy without operational burden, the strict international regulations enacted for safe biopharmaceuticals. Notably, a scaled substitute for open-field transgenics has been made possible by developments in automated agroinfiltration platforms that run in automated processes, enabling for temporary expression in large-scale greenhouses [140]. These facilities provide constant antigen titers and GMP-compliant batch release testing that is comparable to that utilized in mammalian cell cultures by simulating predictability obtainable in bioreactor-like environments in a plant production system.

Supply Chain Integration from Cultivation to Post-Harvest Downstream Processing

Among other factors, crops of interest also require strong supply chain integration that connects processes beginning from plant cultivation, their harvesting, downstream processing and final distribution in order for edible vaccines to satisfy scalability at high standards. This is because edible vaccines require a different purification and distribution process than traditional vaccines, which are purified and given out in vials. They can be given as minimally processed biomass, such as lyophilized plant tissue, or as purified antigens, but their packaging requires they being contained in capsules or tablets [141]. However, post-harvest processing is subject to specific restrictions for each delivery route. Because proteolysis and oxidation can quickly impair potency, it is crucial for edible tissue-based vaccines to keep antigen stable during storage, transportation, and distribution in addition to establishing a regulated environment for their growth [142].

Techniques including spray-drying, freeze-drying and ultimately, encapsulation into cellulose or starch matrices have been used to increase shelf life in non-refrigerated environments in order to make this feasible. For deployment in environments with limited resources, this is particularly crucial [143, 144]. Additionally, pathogen testing, uniformity evaluation, and other procedures like standardization of antigen dosage per unit biomass are necessary steps for the integration of downstream operations with upstream cultivation. Both pharmaceutical integrity and agricultural scalability are maintained by edible vaccine crops thanks to a well-designed logistics system that takes inspiration from commercial food supply chains.

Closed-loop production workflow for edible vaccine crops

Close-loop production workflow is notable due to its comprehensive bioprocess engineering paradigm that incorporates all phases ranging from genetic design to patient delivery. This is most impressively usually within a regulated and traceable framework. This workflow involves growing crops in contained and tightly monitored environments, harvesting them in GMP-certified circumstances, and processing them in facilities built for handling pharmaceutical-grade food [145]. To track each production lot from seed to end-user distribution, closed-loop systems use digital technologies for traceability, such as blockchain platforms and QR-coded batch identification [146]. In addition to preventing counterfeiting and guaranteeing accountability, this step offers post-market surveillance data that is essential for maintaining public confidence.

Additionally, adaptive manufacturing as targeted strategy is now made possible by closed-loop workflows. For instance, a cholera vaccine crop can be converted to an influenza antigen crop in the same facility by simply changing the genetic cassettes adopted for the process, temporary expression or agroinfiltration. Also, compatibility with modular production settings, that in some cases are situated adjacent to areas that are prone to outbreaks, is another advantage of adopting closed-loop systems in anufacturing. This lessens dependency on international cold-chain logistics and gives local health services the ability to respond quickly [147]. However, because edible vaccines fall under both pharmaceutical and agricultural domains, making cross-border GMP certification challenging, such integration necessitates international regulatory frameworks being adhered to [148].



Fig 3.0: A comprehensive schematic showing a range of methods for the development of plant-based edible vaccines [149]

7. Regulatory, Biosafety, and Containment Strategies

With some of the concerns of edible vaccines production that includes production processes, distribution and feasibility of products, biocontainment remains a primary concern. This is because the right techniques are vital in ensuring that the edible vaccines do not inadvertently leak into the environment where they pose a high risk of, if not contained, crossbreeding with wild species or infiltrate undesired ecosystems [150, 151]. Regulatory systems place a strong emphasis on containment strategies that are both genetic and physical. Some of the measures to contain this include tight-controlling greenhouses, restricting access fields, and spatial isolation strategies that reduce gene flow, all serving as effective strategies for physical biocontainment. On the other hand, genetic techniques include the creation of inducible promoters that only produce the antigen under specific circumstances and transplastomic plants that limit transgene inheritance through pollen. When combined, these strategies help to lower the likelihood of unintentional spread, boosting public confidence and adhering to global biosafety regulations [152].

Digital traceability technologies are becoming a supplementary layer of supervision beyond molecular protections. Real-time distribution pathway verification has been revolutionized with the use of technology like blockchain-based tracking supplemented with AI-driven supply chain monitoring. The use of these two techniques minimizes the possibility of diversion or the introduction of counterfeit vaccination goods while guaranteeing that edible vaccine supplies reach their target audiences [153, 154]. These two strategies, if combined rightly with digital traceability and biological containment, work in tandem to create a comprehensive regulatory framework that strengthens public confidence and safety.

8. Conclusion — Translational Pathways for Next-Generation Edible Vaccines

With growing attention across several laboratories in edible vaccines and its intriguing convergence of immunology, plant biotechnology, and global health policy, the development of edible vaccines also illustrates how people's conceptions of preventative care have changed in a more connected world. From genome-edited expression systems to antigen stabilization in plant matrices, scientific advances over the last 20 years have continuously shown proof-of-concept and, more and more, scaling potential. Vaccines embedded in staple foods, formerly rejected as an unorthodox idea, are now considered a viable supplement to traditional vaccination pipelines, especially in resource-constrained settings where cold-chain logistics are still prohibitive [155, 156].

However, the real potential of edible vaccines remains to enhance current approaches rather than replace them. Edible vaccine crops could revolutionize preventive care in modern day by providing a decentralized delivery mechanism at community level much like oral polio vaccines did in the twentieth century when they revolutionized mass immunization mechanisms [157]. By drawing comparisons, it can be argued that, just as polio vaccination demonstrated the practical benefits of oral rather than parenteral administration, edible vaccines now apply this reasoning to an agricultural framework, combining immunization and food security in a single innovation.

However, whether these vaccines become mainstays of public health or remain laboratory experiments will depend on regulatory and biosafety considerations. Despite unmistakable scientific proof of safety, past debates over genetically modified organisms (GMOs) show the public's ambivalence against the implementation of biotechnologies.

Lessons learned from the adoption of genetically modified rice and maize are helpful in this regard: broad acceptability depends on culturally appropriate communication tactics that match innovation with regional nutritional and social customs in addition to regulatory approval [158]. If communities are involved early on in ethics, and trust in the area of deployment, edible vaccines embedded in well-known foods like rice, bananas, and tomatoes may have a special resonance.

In the future, distribution networks will probably incorporate blockchain-based verification systems and digital traceability frameworks to handle biosafety and authenticity. Current containment technologies, such as site-specific recombinases and chloroplast engineering, indicate a emerging shift in operation, where biocontainment is becoming more fundamental rather than extrinsic, although early-stage gene-edited crops originally sparked concerns about "escape" into uncontrolled ecosystems [159]. From reactive oversight to proactive, embedded safety-by-design structures, this progression reflects the larger trajectory of biotechnology.

In order to combat re-emerging infectious dangers like cholera or pandemic influenza, the first worldwide health campaigns utilizing edible vaccinations in conjunction with their injectable counterparts may be implemented within the decade to come. It is possible to also witness integrated nutraceutical-immunological platforms by the middle of the century, where it is conventional to have dietary staples serve as both a source of nutrition and an immunization, a practice with the prospect of integrating safety into food systems. Such a shift will broaden the definition of what traditional societies view as "medicine" in addition to redefining "vaccination."

Ultimately, edible vaccines represent a translational philosophy rather than merely being a scientific advancement. They challenge societies, scientists, and policymakers to reconsider the division between public health, medicine, and agriculture. In the same way that antibiotics revolutionized medicine in the 20th century, edible vaccines may serve as a fulcrum for the 21st century's efforts to provide universal, affordable, and sustainable immunization. It will take more than just laboratory skillset to make this promise a reality; it will also require the willingness to negotiate and reconsider regulatory landscapes in public health policy making, an extra commitment to build public confidence, and a special focus on the interdisciplinary collaboration that edible vaccines so gracefully require [160].

9. References

1. Fischer R, Liao YC, Hoffmann K, Schillberg S, Emans N. Molecular farming of recombinant antibodies in plants. Biol Chem. 1999;380(7-8):825-39.
2. Fischer R, Drossard J, Commandeur U, Schillberg S, Emans N. Towards molecular farming in the future: moving from diagnostic protein and antibody production in microbes to plants. Biotechnol Appl Biochem. 1999;30(2):101-8.
3. Mamedov T, Yuksel D, Ilgın M, Gürbüzaslan I, Gulec B, Mammadova G, *et al*. Production and characterization of nucleocapsid and RBD cocktail antigens of SARS-CoV-2 in *Nicotiana benthamiana* plant as a vaccine candidate against COVID-19. Vaccines. 2021;9(11):1337. doi:10.3390/vaccines9111337.
4. Sahoo A, Mandal AK, Dwivedi K, Kumar V. A cross talk between the immunization and edible vaccine: current challenges and future prospects. Life Sci. 2020;261:118343. doi:10.1016/j.lfs.2020.118343.
5. Fischer R, Emans N. Molecular farming of pharmaceutical proteins. Transgenic Res. 2000;9(4-5):279-99. doi:10.1023/A:1008975123362.
6. Sohrab SS. An edible vaccine development for coronavirus disease 2019: the concept. Clin Exp Vaccine Res. 2020;9(2):164-8. doi:10.7774/cevr.2020.9.2.164.
7. Faith VH, Debnath S, Lavanya D, Jerusha V, Madhuri M. Food as a vaccine. Res J Pharm Dos Forms Technol. 2015;7(2):161-5. doi:10.5958/0975-4377.2015.00023.3.
8. Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA, Ramshaw IA. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev. 1999;171(1):27-44. doi:10.1111/j.1600-065X.1999.tb01341.x.
9. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, *et al*. Expression of an immunogenic Ebola immune complex in *Nicotiana benthamiana*. Plant Biotechnol J. 2011;9(7):807-16. doi:10.1111/j.1467-7652.2011.00593.x.
10. Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 2004;5(5):460-4. doi:10.1038/ni0504-460.
11. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A. 1996;93(11):5335-40. doi:10.1073/pnas.93.11.5335.
12. Rigano MM, Alvarez ML, Pinkhasov J, Jin Y, Sala F, Arntzen CJ, *et al*. Production of a fusion protein consisting of the enterotoxigenic *Escherichia coli* heat-labile toxin B subunit and a tuberculosis antigen in *Arabidopsis thaliana*. Plant Cell Rep. 2004;22(7):502-8. doi:10.1007/s00299-003-0718-2.
13. Voinnet O, Rivas S, Mestre P, Baulcombe D. An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus. Plant J. 2003;33(5):949-56. doi:10.1046/j.1365-313X.2003.01676.x.
14. Rashmi J. Plant biotechnology and molecular farming: a new frontier in pharmaceutical innovation. World J Pharm Med Res. 2025;11(4):413-20.
15. Verma D, Daniell H. Chloroplast vector systems for biotechnology applications. Plant Physiol. 2007;145(4):1129-43. doi:10.1104/pp.107.106690.
16. Verma D, Samson NP, Koya V, Daniell H. A protocol for expression of foreign genes in chloroplasts. Nat Protoc. 2008;3(5):739-58. doi:10.1038/nprot.2008.57.
17. Gray BN, Ahner BA, Hanson MR. High-level bacterial cellulase accumulation in chloroplast-transformed tobacco mediated by downstream box fusions. Biotechnol Bioeng. 2009;102(4):1045-54. doi:10.1002/bit.22156.
18. Yu LX, Gray BN, Rymarquis LA, Ahner BA, Hanson MR. Expression of thermostable microbial cellulases in the chloroplasts of nicotine-free tobacco. J Biotechnol. 2007;131(3):362-9. doi:10.1016/j.jbiotec.2007.07.946.
19. Hanson MR, Gray BN, Ahner BA. Chloroplast transformation for engineering of photosynthesis. J Exp Bot. 2013;64(3):731-42. doi:10.1093/jxb/ers324.
20. Kumar S, Hahn FM, Baidoo E, Kahlon TS, Wood DF, McMahan CM, *et al*. Remodeling the isoprenoid

pathway in tobacco by expressing the cytoplasmic mevalonate pathway in chloroplasts. Metab Eng. 2012;14(1):19-28. doi:10.1016/j.ymben.2011.11.005.
21. Saxena B, Subramaniyan M, Malhotra K, Bhavesh NS, Potlakayala SD, Kumar S. Metabolic engineering of chloroplasts for artemisinic acid biosynthesis and impact on plant growth. J Biosci. 2014;39(1):33-41. doi:10.1007/s12038-013-9403-8.
22. Guda C, Lee SB, Daniell H. Stable expression of a biodegradable protein-based polymer in tobacco chloroplasts. Plant Cell Rep. 2000;19(3):257-62. doi:10.1007/s002990050008.
23. Daniell H, Dhingra A, Fernández-San Millán A. Transient foreign gene expression in chloroplasts of cultured tobacco cells after biolistic delivery of chloroplast vectors. Proc Natl Acad Sci U S A. 1990;87(1):88-92. doi:10.1073/pnas.87.1.88.
24. McBride KE, Svab Z, Schaaf DJ, Hogan PS, Stalker DM, Maliga P. Controlled expression of plastid transgenes in plants based on a nuclear DNA-encoded and plastid-targeted T7 RNA polymerase. Proc Natl Acad Sci U S A. 1994;91(15):7301-5. doi:10.1073/pnas.91.15.7301.
25. Barone P, Zhang X, Widholm JM. Tobacco plastid transformation using the feedback-insensitive anthranilate synthase α-subunit of tobacco (ASA2) as a new selectable marker. J Exp Bot. 2009;60(11):3195-202. doi:10.1093/jxb/erp158.
26. Zhang J, Ruf S, Hasse C, Childs L, Scharvin M, Bock R. Full crop protection from an insect pest by expression of long double-stranded RNAs in plastids. Science. 2015;347(6225):991-4. doi:10.1126/science.1261680.
27. Verma D, Kanagaraj A, Jin S, Singh ND, Kolattukudy PE, Daniell H. Chloroplast-derived enzyme cocktails hydrolyse lignocellulosic biomass and release fermentable sugars. Plant Biotechnol J. 2010;8(3):332-50. doi:10.1111/j.1467-7652.2009.00486.x.
28. Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H. The role of heterologous chloroplast sequence elements in transgene integration and expression. Plant Physiol. 2010;152(4):2088-104. doi:10.1104/pp.109.152017.
29. Gisby MF, Mellors P, Madesis P, Ellin M, Laverty H, O'Keefe S, *et al*. A synthetic gene increases TGFβ3 accumulation by 75-fold in tobacco chloroplasts enabling rapid purification and folding into a biologically active molecule. Plant Biotechnol J. 2011;9(5):618-28. doi:10.1111/j.1467-7652.2011.00619.x.
30. De Cosa B, Moar W, Lee SB, Miller M, Daniell H. Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnol. 2001;19(1):71-4. doi:10.1038/83559.
31. Goldschmidt-Clermont M. Transgenic expression of aminoglycoside adenine transferase in the chloroplast: a selectable marker of site-directed transformation of *Chlamydomonas*. Nucleic Acids Res. 1991;19(15):4083-9. doi:10.1093/nar/19.15.4083.
32. Svab Z, Maliga P. High-frequency plastid transformation in tobacco by selection for a chimeric aadA gene. Proc Natl Acad Sci U S A. 1993;90(3):913-7. doi:10.1073/pnas.90.3.913.
33. Day A, Goldschmidt-Clermont M. The chloroplast transformation toolbox: selectable markers and marker removal. Plant Biotechnol J. 2011;9(5):540-53. doi:10.1111/j.1467-7652.2011.00604.x.
34. Shao M, Kershberger I, Bock R. Precise excision of plastid DNA by large serine recombinase Bxb1. Plant Biotechnol J. 2014;12(3):322-9. doi:10.1111/pbi.12139.
35. Sugiyama N, Nakagami H, Mochida K, Daudi A, Tomita M, Shirasu K, *et al*. Large-scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in *Arabidopsis*. Mol Syst Biol. 2008;4:193. doi:10.1038/msb.2008.32.
36. Reiland S, Messerli G, Baerenfaller K, Gerrits B, Endler A, Grossmann J, *et al*. Large-scale *Arabidopsis* phosphoproteome profiling reveals novel chloroplast kinase substrates and phosphorylation networks. Plant Physiol. 2009;150(2):889-903. doi:10.1104/pp.109.138677.
37. Aro EM, Virgin I, Andersson B. Photoinhibition of photosystem II: inactivation, protein damage and turnover. Biochim Biophys Acta. 1993;1143(2):113-34. doi:10.1016/0005-2728(93)90134-2.
38. Komenda J, Sobotka R, Nixon PJ. Assembling and maintaining the photosystem II complex in chloroplasts and cyanobacteria. Curr Opin Plant Biol. 2012;15(3):245-51. doi:10.1016/j.pbi.2012.01.014.
39. Allen JF, Bennett J, Steinback KE, Arntzen CJ. Chloroplast protein phosphorylation couples plastoquinone redox state to distribution of excitation energy between photosystems. Nature. 1981;291(5810):25-9. doi:10.1038/291025a0.
40. Rintamäki E, Martinsuo P, Pursiheimo S, Aro EM. Cooperative regulation of light-harvesting complex II phosphorylation via the plastoquinol and ferredoxin-thioredoxin system in chloroplasts. Proc Natl Acad Sci U S A. 2000;97(21):11644-9. doi:10.1073/pnas.97.21.11644.
41. Bellafiore S, Barneche F, Peltier G, Rochaix JD. State transitions and light adaptation require chloroplast thylakoid protein kinase STN7. Nature. 2005;433(7028):892-5. doi:10.1038/nature03286.
42. Bonardi V, Pesaresi P, Becker T, Schleiff E, Wagner R, Pfannschmidt T, *et al*. Photosystem II core phosphorylation and photosynthetic acclimation require two different protein kinases. Nature. 2005;437(7062):1179-82. doi:10.1038/nature04016.
43. Vainonen JP, Hansson M, Vener AV. STN8 protein kinase in *Arabidopsis thaliana* is specific in phosphorylation of photosystem II core proteins. J Biol Chem. 2005;280(39):33679-86. doi:10.1074/jbc.M505729200.
44. Vainonen JP, Sakuragi Y, Stael S, Tikkanen M, Allahverdiyeva Y, Paakkarinen V, *et al*. Light regulation of CaS, a novel phosphoprotein in the thylakoid membrane of *Arabidopsis thaliana*. FEBS J. 2008;275(8):1767-77. doi:10.1111/j.1742-4658.2008.06335.x.
45. Reiland S, Finazzi G, Endler A, Willig A, Baerenfaller K, Grossmann J, *et al*. Comparative phosphoproteome profiling reveals a function of the STN8 kinase in fine-tuning of cyclic electron flow (CEF). Proc Natl Acad Sci U S A. 2011;108(31):12955-60. doi:10.1073/pnas.1104734108.
46. Baerenfaller K, Grossmann J, Grobei MA, Hull R, Hirsch-Hoffmann M, Yalovsky S, *et al*. Genome-scale proteomics reveals *Arabidopsis thaliana* gene models and proteome dynamics. Science. 2008;320(5878):938-

41. doi:10.1126/science.1157957.
47. Bienvenut WV, Sumpton D, Martinez A, Lilla S, Espagne C, Meinnel T, *et al*. Comparative large scale characterization of plant versus mammal proteins reveals similar and idiosyncratic N-α-acetylation features. Mol Cell Proteomics. 2012;11(6):M111.015131. doi:10.1074/mcp.M111.015131.
48. Polevoda B, Arnesen T, Sherman F. A synopsis of eukaryotic Nα-terminal acetyltransferases: nomenclature, subunits and substrates. BMC Proc. 2009;3(Suppl 6):S2. doi:10.1186/1753-6561-3-S6-S2.
49. Scott DC, Monda JK, Bennett EJ, Harper JW, Schulman BA. N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex. Science. 2011;334(6056):674-8. doi:10.1126/science.1209307.
50. Behnia R, Panic B, Whyte JR, Munro S. Targeting of the Arf-like GTPase Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p. Nat Cell Biol. 2004;6(5):405-13. doi:10.1038/ncb1120.
51. Hwang CS, Shemorry A, Varshavsky A. N-terminal acetylation of cellular proteins creates specific degradation signals. Science. 2010;327(5968):973-7. doi:10.1126/science.1183147.
52. Bienvenut WV, Sumpton D, Martinez A, Lilla S, Espagne C, Meinnel T, *et al*. Comparative large scale characterization of plant versus mammal proteins reveals similar and idiosyncratic N-α-acetylation features. Mol Cell Proteomics. 2012;11(6):M111.015131. doi:10.1074/mcp.M111.015131.
53. Ferrández-Ayela A, Micol-Ponce R, Sánchez-García AB, Alonso-Peral MM, Micol JL, Ponce MR. Mutation of an *Arabidopsis* NatB N-α-terminal acetylation complex component causes pleiotropic developmental defects. PLoS One. 2013;8(11):e80697. doi:10.1371/journal.pone.0080697.
54. Matsuo T, Iida T, Ishiura M. N-terminal acetyltransferase 3 gene is essential for robust circadian rhythm of bioluminescence reporter in *Chlamydomonas reinhardtii*. Biochem Biophys Res Commun. 2012;418(2):342-6. doi:10.1016/j.bbrc.2012.01.027.
55. Van Damme P, Arnesen T, Gevaert K. Protein α-N-acetylation studied by N-terminomics. FEBS J. 2011;278(20):3822-34. doi:10.1111/j.1742-4658.2011.08230.x.
56. Pesaresi P, Gardner NA, Masiero S, Dietzmann A, Eichacker L, Wickner R, *et al*. Cytoplasmic N-terminal protein acetylation is required for efficient photosynthesis in *Arabidopsis*. Plant Cell. 2003;15(8):1817-32. doi:10.1105/tpc.012864.
57. Bischof S, Baerenfaller K, Wildhaber T, Troesch R, Vidi PA, Roschitzki B, *et al*. Plastid proteome assembly without Toc159: photosynthetic protein import and accumulation of N-acetylated plastid precursor proteins. Plant Cell. 2011;23(11):3911-28. doi:10.1105/tpc.111.090944.
58. Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem Sci. 2003;28(6):329-35. doi:10.1016/S0968-0004(03)00090-2.
59. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009;33(1):1-13. doi:10.1016/j.molcel.2008.12.013.
60. Lanouette S, Mongeon V, Figeys D, Couture JF. The functional diversity of protein lysine methylation. Mol Syst Biol. 2014;10:724. doi:10.1002/msb.134974.
61. Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol. 2001;13(3):263-73. doi:10.1016/S0955-0674(00)00208-8.
62. Houtz RL, Poneleit L, Jones SB, Royer M, Stults JT. Posttranslational modifications in the amino-terminal region of the large subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase from several plant species. Plant Physiol. 1992;98(3):1170-4. doi:10.1104/pp.98.3.1170.
63. Mininno M, Brugière S, Pautre V, Gilgen A, Ma S, Ferro M, *et al*. Characterization of chloroplastic fructose 1,6-bisphosphate aldolases as lysine-methylated proteins in plants. J Biol Chem. 2012;287(25):21034-44. doi:10.1074/jbc.M112.359976.
64. Corpas FJ, Chaki M, Leterrier M, Barroso JB. Protein tyrosine nitration: a new challenge in plants. Plant Signal Behav. 2009;4(10):920-3. doi:10.4161/psb.4.10.9468.
65. Gow AJ, Davis CW, Munson D, Ischiropoulos H. Immunohistochemical detection of S-nitrosylated proteins. Methods Mol Biol. 2004;279:167-72. doi:10.1385/1-59259-807-2:167.
66. Corpas FJ, Chaki M, Fernández-Ocaña A, Valderrama R, Palma JM, Carreras A, *et al*. Metabolism of reactive nitrogen species in pea plants under abiotic stress conditions. Plant Cell Physiol. 2008;49(11):1711-22. doi:10.1093/pcp/pcn144.
67. Lozano-Juste J, Colom-Moreno R, León J. *in vivo* protein tyrosine nitration in *Arabidopsis thaliana*. J Exp Bot. 2011;62(10):3501-17. doi:10.1093/jxb/err042.
68. Villarejo A, Burén S, Larsson S, Déjardin A, Monné M, Rudhe C, *et al*. Evidence for a protein transported through the secretory pathway en route to the higher plant chloroplast. Nat Cell Biol. 2005;7(12):1224-31. doi:10.1038/ncb1330.
69. Burén S, Ortega-Villasante C, Blanco-Rivero A, Martínez-Bernardini A, Shutova T, Shevela D, *et al*. Importance of post-translational modifications for functionality of a chloroplast-localized carbonic anhydrase (CAH1) in *Arabidopsis thaliana*. PLoS One. 2011;6(6):e21021. doi:10.1371/journal.pone.0021021.
70. Chen MH, Liu LF, Chen YR, Wu HK, Yu SM. Expression of α-amylases, carbohydrate metabolism, and autophagy in cultured rice cells is coordinately regulated by sugar nutrient. Plant J. 1994;6(5):625-36. doi:10.1046/j.1365-313X.1994.6050625.x.
71. Asatsuma S, Sawada C, Itoh K, Okito M, Kitajima A, Mitsui T. Involvement of α-amylase I-1 in starch degradation in rice chloroplasts. Plant Cell Physiol. 2005;46(6):858-69. doi:10.1093/pcp/pci091.
72. Nanjo Y, Oka H, Ikarashi N, Kaneko K, Kitajima A, Mitsui T, *et al*. Rice plastidial N-glycosylated nucleotide pyrophosphatase/phosphodiesterase is transported from the ER-Golgi to the chloroplast through the secretory pathway. Plant Cell. 2006;18(10):2582-92. doi:10.1105/tpc.105.039842.
73. Gaikwad A, Tewari KK, Kumar D, Chen W, Mukherjee SK. Isolation and characterisation of the cDNA encoding a glycosylated accessory protein of pea chloroplast DNA polymerase. Nucleic Acids Res. 1999;27(15):3120-9. doi:10.1093/nar/27.15.3120.
74. Elrouby N, Coupland G. Proteome-wide screens for small ubiquitin-like modifier (SUMO) substrates identify *Arabidopsis* proteins implicated in diverse

biological processes. Proc Natl Acad Sci U S A. 2010;107(40):17415-20. doi:10.1073/pnas.1009022107.
75. López-Torrejón G, Guerra D, Catalá R, Salinas J, del Pozo JC. Identification of SUMO targets by a novel proteomic approach in plants. J Integr Plant Biol. 2013;55(1):96-107. doi:10.1111/jipb.12012.
76. Vierstra RD. The expanding universe of ubiquitin and ubiquitin-like modifiers. Plant Physiol. 2012;160(1):2-14. doi:10.1104/pp.112.200667.
77. Brogna R, Oldenhof H, Sieme H, Figueiredo C, Kerrinnes T, Wolkers WF. Increasing storage stability of freeze-dried plasma using trehalose. PLoS One. 2020;15(6):e0234502. doi:10.1371/journal.pone.0234502.
78. Mari E, Fengler VH, Truzzi F, Paganelli A, Mattoli V, Petrarca C. Trehalose effect on the aggregation of model proteins into fibrils. Life. 2020;10(5):60. doi:10.3390/life10050060.
79. Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19-40. doi:10.1038/nrd.2018.183.
80. Kwon KC, Daniell H. Oral delivery of protein drugs bioencapsulated in plant cells. Mol Ther. 2016;24(8):1342-50. doi:10.1038/mt.2016.115.
81. Shukla R, Cheryan M. Zein: the industrial protein from corn. Ind Crop Prod. 2001;13(3):171-92. doi:10.1016/S0926-6690(00)00064-9.
82. Patel A, Hu Y, Tiwari JK, Velikov KP. Synthesis and characterisation of zein–curcumin colloidal particles. Soft Matter. 2010;6(24):6192-9. doi:10.1039/c0sm00824a.
83. Karthikeyan K, Vijayalakshmi E, Korrapati PS. Selective interactions of zein microspheres with different class of drugs: an *in vitro* and in silico analysis. AAPS PharmSciTech. 2014;15(5):1172-80. doi:10.1208/s12249-014-0150-9.
84. Penalva R, González-Navarro CJ, Gamazo C, Esparza I, Irache JM. Zein nanoparticles for oral delivery of quercetin: pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia. Nanomedicine. 2017;13(1):103-10. doi:10.1016/j.nano.2016.08.033.
85. Luo Y, Zhang B, Whent M, Yu LL, Wang Q. Preparation and characterization of zein/chitosan complex for encapsulation of α-tocopherol, and its *in vitro* controlled release study. Colloids Surf B Biointerfaces. 2011;85(2):145-52. doi:10.1016/j.colsurfb.2011.02.020.
86. Troncoso OP, Torres FG. Non-conventional starch nanoparticles for drug delivery applications. Med Devices Sens. 2020;3(5):e10111. doi:10.1002/mds3.10111.
87. Moreno-Mendieta S, Barrios-Payán J, Mata-Espinosa D, Sánchez S, Hernández-Pando R, Rodríguez-Sanoja R. Raw starch microparticles have immunostimulant activity in mice vaccinated with BCG and challenged with *Mycobacterium tuberculosis*. Vaccine. 2017;35(37):5123-30. doi:10.1016/j.vaccine.2017.07.055.
88. Qiu C, Wang C, Gong C, McClements DJ, Jin Z, Wang J. Advances in research on preparation, characterization, interaction with proteins, digestion and delivery systems of starch-based nanoparticles. Int J Biol Macromol. 2020;152:117-25. doi:10.1016/j.ijbiomac.2020.02.313.
89. Antonella DS, Annabella V, Silvia DG. Plant-derived nutraceuticals and immune system modulation: an evidence-based overview. Vaccines. 2020;8(3):468. doi:10.3390/vaccines8030468.
90. Wen CC, Chen HM, Yang NS. Developing phytocompounds from medicinal plants as immunomodulators. Adv Bot Res. 2012;62:197-272. doi:10.1016/B978-0-12-394591-4.00004-0.
91. Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 2020;181(5):969-77. doi:10.1016/j.cell.2020.04.042.
92. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506. doi:10.1038/s41422-020-0332-7.
93. Michel J, Mezouar S, Sereme Y, Chanez P, Vitte J, Dubus JC, *et al*. Microbiome and the immune system: from a healthy steady-state to allergy-associated disruption. Hum Microbiome J. 2018;10:11-20. doi:10.1016/j.humic.2018.10.001.
94. Wang C, Hou Y, Lv Y, Chen S, Zhou X, Zhu R, *et al*. *Echinacea purpurea* extract affects the immune system, global metabolome, and gut microbiome in Wistar rats. J Agric Sci. 2017;9(12):1-13. doi:10.5539/jas.v9n12p1.
95. Sun Y, Chen S, Wei R, Xie X, Wang C, Fan S, *et al*. Metabolome and gut microbiota variation with long-term intake of *Panax ginseng* extracts on rats. Food Funct. 2018;9(7):3547-56. doi:10.1039/C8FO00025E.
96. Chen D, Chen G, Ding Y, Wan P, Peng Y, Chen C, *et al*. Polysaccharides from the flowers of tea (*Camellia sinensis* L.) modulate gut health and ameliorate cyclophosphamide-induced immunosuppression. J Funct Foods. 2019;61:103470. doi:10.1016/j.jff.2019.103470.
97. Catanzaro M, Corsini E, Rosini M, Racchi M, Lanni C. Immunomodulators inspired by nature: a review on curcumin and *Echinacea*. Molecules. 2018;23(11):2778. doi:10.3390/molecules23112778.
98. Pillai S, Pillai C, Mitscher LA, Cooper R. Use of quantitative flow cytometry to measure ex vivo immunostimulant activity of *Echinacea*: the case for polysaccharides. J Altern Complement Med. 2007;13(6):625-34. doi:10.1089/acm.2007.7037.
99. Chandran U, Patwardhan B. Network ethnopharmacological evaluation of the immunomodulatory activity of *Withania somnifera*. J Ethnopharmacol. 2017;197:250-6. doi:10.1016/j.jep.2016.07.073.
100. Kaur P, Makanjuola VO, Arora R, Singh B, Arora S. Immunopotentiating significance of conventionally used plant adaptogens as modulators in biochemical and molecular signalling pathways in cell-mediated processes. Biomed Pharmacother. 2017;95:1815-29. doi:10.1016/j.biopha.2017.09.081.
101. Jones JM. CODEX-aligned dietary fiber definitions help to bridge the 'fiber gap'. Nutr J. 2014;13:34. doi:10.1186/1475-2891-13-34.
102. Ferreira SS, Passos CP, Madureira P, Vilanova M, Coimbra MA. Structure-function relationships of immunostimulatory polysaccharides: a review. Carbohydr Polym. 2015;132:378-96. doi:10.1016/j.carbpol.2015.05.079.
103. Yao JF, Wang ZX, Zhang XY, Zhang RF. Study on immunomodulatory effect of *Astragalus* polysaccharide

on mice peritoneal macrophage. J Henan Univ. 2005;24:34-6.
104. Lee KY, Jeon YJ. Macrophage activation by polysaccharide isolated from *Astragalus membranaceus*. Int Immunopharmacol. 2005;5(7-8):1225-33. doi:10.1016/j.intimp.2005.02.020.
105. Li R, Chen W, Wang W, Tian W, Zhang X. Extraction, characterization of *Astragalus* polysaccharides and its immune modulating activities in rats with gastric cancer. Carbohydr Polym. 2009;78(4):738-42. doi:10.1016/j.carbpol.2009.06.005.
106. Luu M, Visekruna A. Short-chain fatty acids: bacterial messengers modulating the immunometabolism of T cells. Eur J Immunol. 2019;49(6):842-8. doi:10.1002/eji.201848009.
107. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-45. doi:10.1016/j.cell.2016.05.041.
108. Yaqoob P. Monounsaturated fatty acids and immune function. Eur J Clin Nutr. 2002;56(Suppl 3):S9-13. doi:10.1038/sj.ejcn.1601477.
109. Jeffery NM, Cortina M, Newsholme EA, Calder PC. Effects of variations in the proportions of saturated, monounsaturated and polyunsaturated fatty acids in the rat diet on spleen lymphocyte functions. Br J Nutr. 1997;77(5):805-23. doi:10.1079/BJN19970078.
110. Mastrangelo AM, Jeitner TW, Eaton JW. Oleic acid increases cell surface expression and activity of CD11b on human neutrophils. J Immunol. 1998;161(8):4268-75.
111. Ferrante A, Goh D, Harvey DP, Robinson BS, Hii CS, Bates EJ, *et al*. Neutrophil migration inhibitory properties of polyunsaturated fatty acids: the role of fatty acid structure, metabolism, and possible second messenger systems. J Clin Invest. 1994;93(3):1063-70. doi:10.1172/JCI117053.
112. Lladó V, Gutiérrez A, Martínez J, Casas J, Terés S, Higuera M, *et al*. Minerval induces apoptosis in Jurkat and other cancer cells. J Cell Mol Med. 2010;14(3):659-70. doi:10.1111/j.1582-4934.2008.00527.x.
113. Cury-Boaventura MF, Pompéia C, Curi R. Comparative toxicity of oleic acid and linoleic acid on Jurkat cells. Clin Nutr. 2004;23(4):721-32. doi:10.1016/j.clnu.2003.12.004.
114. Cury-Boaventura MF, Pompéia C, Curi R. Comparative toxicity of oleic acid and linoleic acid on Raji cells. Nutrition. 2005;21(3):395-405. doi:10.1016/j.nut.2004.07.007.
115. Viladomiu M, Hontecillas R, Lu P, Bassaganya-Riera J. Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med. 2013;2013:789764. doi:10.1155/2013/789764.
116. Yuan G, Chen X, Li D. Modulation of peroxisome proliferator-activated receptor gamma (PPARγ) by conjugated fatty acid in obesity and inflammatory bowel disease. J Agric Food Chem. 2015;63(7):1883-95. doi:10.1021/jf505647b.
117. Ji XQ, Du JF, Chen G. Comparison of perioperative immune function status in colorectal cancer patients and immune regulatory function of drugs. Pract J Cancer. 2011;26(4):331-4.
118. Brinkeborn RM, Shah DV, Degenring FH. Echinaforce and other *Echinacea* fresh plant preparations in the treatment of the common cold: a randomized, placebo-controlled, double-blind clinical trial. Phytomedicine. 1999;6(1):1-6. doi:10.1016/S0944-7113(99)80027-0.
119. Karsch-Völk M, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K, Linde K. *Echinacea* for preventing and treating the common cold. Cochrane Database Syst Rev. 2014;2014(2):CD000530. doi:10.1002/14651858.CD000530.pub3.
120. Richter J, Svozil V, Král V, Rajnohová Dobiašová L, Stiborová I, Vetvicka V. Clinical trials of yeast-derived β-(1,3) glucan in children: effects on innate immunity. Ann Transl Med. 2014;2(2):15. doi:10.3978/j.issn.2305-5839.2014.02.01.
121. Richter J, Svozil V, Král V, Rajnohová Dobiašová L, Stiborová I, Vetvicka V. β-glucan affects mucosal immunity in children with chronic respiratory problems under physical stress: clinical trials. Ann Transl Med. 2015;3(4):52. doi:10.3978/j.issn.2305-5839.2015.03.20.
122. Vetvicka V, Richter J, Svozil V, Rajnohová Dobiašová L, Král V. Placebo-driven clinical trials of yeast-derived β-(1,3) glucan in children with chronic respiratory problems. Ann Transl Med. 2013;1(3):26. doi:10.3978/j.issn.2305-5839.2013.07.01.
123. Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy. 2013;5(11):1177-82. doi:10.2217/imt.13.126.
124. Verma D, Daniell H. Chloroplast vector systems for biotechnology applications. Plant Physiol. 2007;145(4):1129-43. doi:10.1104/pp.107.106690.
125. Maliga P. Plastid transformation in higher plants. Annu Rev Plant Biol. 2004;55:289-313. doi:10.1146/annurev.arplant.55.031903.141633.
126. Bock R, Warzecha H. Solar-powered factories for new vaccines and antibiotics. Trends Biotechnol. 2010;28(5):246-52. doi:10.1016/j.tibtech.2010.01.007.
127. Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med. 2002;8(7):324-9. doi:10.1016/S1471-4914(02)02373-1.
128. Marsian J, Lomonossoff GP. Molecular pharming—VLPs made in plants. Curr Opin Biotechnol. 2016;37:201-6. doi:10.1016/j.copbio.2015.12.007.
129. Chen Q, Lai H, Hurtado J, Stahnke J, Leuzinger K, Dent M. Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins. Adv Tech Biol Med. 2013;1(1):103. doi:10.4172/atbm.1000103.
130. Takeyama N, Kiyono H, Yuki Y. Plant-based vaccines for oral delivery of immunological protection: targeting mucosal immune responses. Curr Top Microbiol Immunol. 2012;354:57-78. doi:10.1007/82_2011_161.
131. Corrado G, Karali M. Inducible gene expression systems and plant biotechnology. Biotechnol Adv. 2009;27(6):733-43. doi:10.1016/j.biotechadv.2009.05.006.
132. Moon H, Park SJ, Park JS, Han JS, Kim YS. Inducible gene expression systems in transgenic plants: current status and future prospects. Plant Cell Rep. 2021;40(2):245-62. doi:10.1007/s00299-020-02622-2.
133. Padidam M. Chemically regulated gene expression in

plants. Curr Opin Plant Biol. 2003;6(2):169-77. doi:10.1016/S1369-5266(03)00008-0.
134. Harmer SL. The circadian system in higher plants. Annu Rev Plant Biol. 2009;60:357-77. doi:10.1146/annurev.arplant.043008.092054.
135. Gleba Y, Klimyuk V, Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol. 2007;18(2):134-41. doi:10.1016/j.copbio.2007.03.002.
136. Mascia T, Gallitelli D. Synergies and antagonisms in virus interactions. Plant Sci. 2016;252:176-92. doi:10.1016/j.plantsci.2016.07.003.
137. Tusé D, Nandi S, McDonald KA, Buyel JF. The emergency response capacity of plant-based biopharmaceutical manufacturing—what it is and what it could be. Front Plant Sci. 2014;5:620. doi:10.3389/fpls.2014.00620.
138. Sparrow PAC, Irwin JA, Dale PJ, Twyman RM, Ma JK. Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Res. 2007;16(2):147-61. doi:10.1007/s11248-006-9033-5.
139. Daniell H, Jin S, Zhu XG, Gitzendanner MA, Soltis DE, Soltis PS. Green giant—a tiny chloroplast genome with mighty power to produce high-value proteins: history and phylogeny. Plant Biotechnol J. 2021;19(2):430-47. doi:10.1111/pbi.13567.
140. Holtz BR, Berquist BR, Bennett LD, Kommineni VJ, Munigunti RK, White EL, *et al*. Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant Biotechnol J. 2015;13(8):1180-90. doi:10.1111/pbi.12469.
141. Twyman RM, Schillberg S, Fischer R. The production of vaccines and therapeutic antibodies in plants. Adv Biochem Eng Biotechnol. 2005;99:107-41. doi:10.1007/b99978.
142. Kwon KC, Daniell H. Low-cost oral delivery of protein drugs bioencapsulated in plant cells. Plant Biotechnol J. 2015;13(8):1017-22. doi:10.1111/pbi.12471.
143. Lee J, Jin S, Park S, Yoo SM, Choi S, Kim H, *et al*. Stabilization of plant-produced therapeutic proteins using carrier matrices. Biotechnol Adv. 2020;40:107500. doi:10.1016/j.biotechadv.2019.107500.
144. Ma JK, Christou P, Chikwamba R, Haydon H, Paul M, Ferrer MP, *et al*. Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies. Plant Biotechnol J. 2013;11(9):1029-33. doi:10.1111/pbi.12127.
145. Capell T, Twyman RM, Armario-Najera V, Ma JK, Schillberg S, Christou P. Potential applications of plant biotechnology against SARS-CoV-2. Trends Plant Sci. 2020;25(7):635-43. doi:10.1016/j.tplants.2020.04.009.
146. Kamle S, Kumar P, Patra JK, Bajpai VK, Kumar A, Pandey A, *et al*. Current perspectives on genetically modified crops and detection methods. 3 Biotech. 2017;7(3):219. doi:10.1007/s13205-017-0810-0.
147. McDonald KA, Holtz RB. From farm to finger prick—a perspective on how plants can help in the fight against COVID-19. Front Bioeng Biotechnol. 2020;8:782. doi:10.3389/fbioe.2020.00782.
148. Fischer R, Buyel JF. Molecular farming—the slope of enlightenment. Biotechnol Adv. 2020;40:107519. doi:10.1016/j.biotechadv.2019.107519.
149. Plantharayil A, Rekha V, John J, Gopinath D, Sadanandan G, Jacob A, *et al*. Plant based edible vaccines against poultry diseases: a review. Adv Anim Vet Sci. 2014;2(5):305-11. doi:10.14737/journal.aavs/2014/2.5.305.311.
150. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. 2001;6(5):219-26. doi:10.1016/S1360-1385(01)01922-7.
151. Clarke JL, Daniell H. Plastid biotechnology for crop production: present status and future perspectives. Plant Mol Biol. 2011;76(3-5):211-20. doi:10.1007/s11103-011-9767-z.
152. Menary J, Hobbs M, Balan V, Daniell H, Luque R, Vakili B, *et al*. Plant-based vaccines: technologies and applications. Plant Biotechnol J. 2022;20(6):1212-29. doi:10.1111/pbi.13794.
153. McMahon A, Roberts RJ. Blockchain in healthcare: applications, challenges and future trends. Health Informatics J. 2021;27(2):14604582211011218. doi:10.1177/14604582211011218.
154. Kamle S, Kumar P, Patra JK, Bajpai VK, Kumar A. Plant molecular farming of edible vaccines and therapeutics: scope and regulatory issues. J Food Drug Anal. 2019;27(3):622-31. doi:10.1016/j.jfda.2019.04.004.
155. Daniell H, Singh ND, Mason H, Streatfield SJ. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 2009;14(12):669-79. doi:10.1016/j.tplants.2009.09.009.
156. Rybicki EP. Plant-based vaccines against viruses. Virol J. 2014;11:205. doi:10.1186/s12985-014-0205-0.
157. Tacket CO. Plant-based oral vaccines: results of human trials. Curr Top Microbiol Immunol. 2009;332:103-17. doi:10.1007/978-3-540-70868-1_6.
158. Qaim M. Role of new plant breeding technologies for food security and sustainable agricultural development. Appl Econ Perspect Policy. 2020;42(2):129-50. doi:10.1002/aepp.13044.
159. Moon J, Lim J, Park S. Biocontainment strategies for genetically modified plants: progress and perspectives. Plant Biotechnol J. 2019;17(1):32-46. doi:10.1111/pbi.13034.
160. Kwon KC, Daniell H. Low-cost oral delivery of protein drugs bioencapsulated in plant cells. Plant Biotechnol J. 2015;13(8):1017-22. doi:10.1111/pbi.12471.
161. Jin S, Daniell H. The engineered chloroplast genome just got smarter. Trends Plant Sci. 2015;20(10):622-40. doi:10.1016/j.tplants.2015.07.004.
162. Lehtimäki N, Koskela MM, Mulo P. Posttranslational modifications of chloroplast proteins: an emerging field. Plant Physiol. 2015;168(3):768-75. doi:10.1104/pp.15.00117.
163. Antonella DS, Annabella V, Silvia DG. Plant-derived nutraceuticals and immune system modulation: an evidence-based overview. Vaccines. 2020;8(3):468. doi:10.3390/vaccines8030468.